OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 8,333 CORT derivative securities | OQRO

Home
Insider trades
Corcept Therapeutics
Officer exercised or converted 8,333 CORT derivative securities

Insider trades

Insider trade

Officer exercised or converted 8,333 CORT derivative securities

Traded Oct 2, 2026 · Filed Oct 6, 2026

CORCorcept TherapeuticsCORT

8,333
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 2, 2026
Reporting period: Not applicable
Filed with the SEC: Oct 6, 2026

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001193125-26-414688

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Oct 6, 2026, 3:58 AM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CORCEPT THERAPEUTICS INC

Issuer CIK

1088856

Ticker

CORT

Reporting person

Roberto Wandenkolk Vieira

Relationship

Officer

Officer title

President, Oncology

Security

Stock option (right to buy)

Table

Derivative (Table II)

Transaction date

Oct 2, 2026

Transaction code

Shares / units

8,333

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

133,334

Ownership form

Direct

Amendment

Footnotes from the filing

Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

Around the same time

Roberto Wandenkolk VieiraPresident, Oncology

Filed yesterday

8,333Shares · @ $21.63

Traded Oct 2 · filed 4 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Roberto Wandenkolk Vieira (President, Oncology) sold ~$126K of Corcept Therapeutics

Scheduled in advanceFiled yesterday

Roberto Wandenkolk Vieira (President, Oncology) sold ~$241K of Corcept Therapeutics

Scheduled in advanceFiled yesterday